Background: Apatinib has been proved to be effective and well tolerated among patients in
phase II and III studies. Here, we evaluated the safety and effectiveness of apatinib in …

Purpose To investigate the efficacy and safety of apatinib mesylate (AM) in treating
advanced non-small cell lung cancer (aNSCLC) with wild or unknown epidermal growth …

Objectives: To evaluate the clinical effect of apatinib combined with chemotherapy in the
treatment of advanced non-small cell lung cancer (NSCLC). Methods: Eighty patients with …

Objective Anlotinib is an oral novel multi-target tyrosine kinase inhibitor targeting vascular
endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth …

Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase
II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to …

Introduction: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor
receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both …

Methods: This is a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Apatinib or matching placebo, 850 mg, po, qd, 28 days as one cycle. Primary outcomes were …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC)
represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity …

8019^ Background: Improved disease control with continuation of EGFR inhibition beyond
progression has been suggested in retrospective/non-randomized studies, however, this …

Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …